Jupiter Endovascular, Inc. announced that the full results of the SPIRARE II pivotal trial, evaluating the company’s Vert ...

Gore & Associates announced FDA approval of an expanded indication for the company’s Viabahn VBX balloon expandable e ...

A summary of four recent studies evaluating locoregional therapies for hepatocellular carcinoma and percutaneous ablation for ...

Penumbra, Inc. announced that the FDA has granted clearance for the treatment of deep vein thrombosis (DVT) to the company&rsqu ...

Stryker Peripheral Vascular announced that the American Medical Association (AMA) Current Procedural Terminology (CPT) ...

The ELEGANCE registry, which focuses on historically underrepresented populations to generate real-world evidence, evaluated en ...

A study of computer-assisted vacuum thrombectomy (CAVT) met its predefined primary effectiveness and safety endpoints for the t ...

Endovascular Engineering, Inc. (E2), a developer of technology for venous thromboembolism, announced FDA 510(k) clearance for b ...

Six-month results from Esprit BTK PAS were reported in patients with chronic limb-threatening ischemia (CLTI) treated with the ...

A secondary analysis of the randomized SirPAD trial demonstrated lower rates of target-lesion revascularization (TLR) and major ...

One-year results from the prospective, multicenter, single-arm PROMISE III trial evaluated transcatheter arterialization of the ...

A post hoc analysis of the randomized HI-PEITHO study examined potential predictors of major bleeding in patients with acute in ...